Mesalazina Sandoz

Mesalazine, the active ingredient in Mesalazina Sandoz, is a 5‑aminosalicylic acid (5‑ASA) presented as a rectal formulation for rectal use. It treats ulcerative colitis and other inflammatory bowel disease in adults by delivering the drug directly to the colon where it exerts local anti‑inflammatory activity.

GNH USA supplies Mesalazina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for global markets.

Mesalazina Sandoz is used in the management of inflammatory bowel disease, primarily targeting colonic inflammation.

Ulcerative colitis: induces and maintains remission of colonic inflammation. Crohn’s disease (colonic involvement): reduces symptoms and mucosal inflammation. Maintenance therapy: helps prevent relapse in patients with ulcerative colitis in remission.

Mesalazina Sandoz may be associated with a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Headache - Nausea - Abdominal pain - Diarrhea - Rectal irritation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Blood dyscrasias such as neutropenia - Hepatotoxicity - Interstitial nephritis - Acute pancreatitis

Before initiating therapy, several precautionary measures should be considered.

Dose adjustment: renal impairment may require reduced dose. Monitor: liver function tests should be performed periodically. Avoid: concurrent use with NSAIDs may increase toxicity. Pregnancy: safety not established; use only if benefit outweighs risk. Breastfeeding: unknown; consider potential risk to infant. Store at room temperature: keep in original container, protect from moisture and light.

Mesalazina Sandoz can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Anticoagulants such as warfarin: increased bleeding risk. - Sulfonamides: additive renal toxicity. - Live vaccines: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Oral corticosteroids: may increase risk of side effects. - Diuretics: may affect renal clearance of mesalazine. - Methotrexate: potential additive toxicity.